ReviewOxidative medicine and cellular longevity2012
Preclinical and clinical evidence of antioxidant effects of antidepressant agents: implications for the pathophysiology of major depressive disorder.
Review in Oxidative medicine and cellular longevity, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 3 syntheses or guidelines pooled it, 199 citations in OpenAlex.
- L-Carnitine in the Treatment of Psychiatric and Neurological Manifestations: A Systematic Review.Nutrients · 2024Pooled it
- Association between dietary caffeine, coffee, and tea consumption and depressive symptoms in adults: A systematic review and dose-response meta-analysis of observational studies.Frontiers in nutrition · 2023Pooled it
- Non-alcoholic beverage consumption and risk of depression: epidemiological evidence from observational studies.European journal of clinical nutrition · 2018Pooled it
- Effects of N-acetylcysteine on oxidative stress biomarkers, depression, and anxiety symptoms in patients with multiple sclerosis.Neuropsychopharmacology reports · 2023Trial
- The effects of crocin on psychological parameters in patients under methadone maintenance treatment: a randomized clinical trial.Substance abuse treatment, prevention, and policy · 2019Trial
- JZ-1201 modulates depressive-like behaviors in rats through targeting catalase.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Metabolomic signatures of SSRI exposure during neural differentiation and correlation of lysophosphatidylcholines with early symptoms of neurodevelopmental disorders.EBioMedicine · 2026Article
- Targeting Pain and Depression in Alzheimer's Disease: Translational Insights and Emerging Treatments.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Parallel Pathways, Divergent Outcomes: Adipose Tissue-Neural Crosstalk in Depression and Obesity.Journal of clinical medicine · 2025Review
- Oxidative stress and cognitive function in Chinese patients with major depressive disorder: the mediating role of depression severity.BMC psychiatry · 2025Article
- Targeting Oxidative Stress for Disease.International journal of molecular sciences · 2025Article
- The Restoration of Energy Pathways Indicates the Efficacy of Ketamine Treatment in Depression: A Metabolomic Analysis.CNS neuroscience & therapeutics · 2025Article
- What is the relationship between exposure to environmental pollutants and severe mental disorders? A systematic review on shared biological pathways.Brain, behavior, & immunity - health · 2025Review
- Lower distress intolerance is associated with higher glutathione levels in adolescent cannabis users.Pharmacology, biochemistry, and behavior · 2024Article
- Review
- Comparing the Effects of Selenium-Enriched Yeast and Sodium Selenite Supplementation on Postpartum Depression and Sexual Satisfaction: A Triple-Blind Controlled Clinical Trial.Journal of caring sciences · 2024Article
- Allostatic Load and Metabolic Syndrome in Depressed Patients: A Cross-Sectional Analysis.Depression and anxiety · 2024Article
- Agomelatine prevented depression in the chronic restraint stress model through enhanced catalase activity and halted oxidative stress.PloS one · 2024Article
- The Effect of Antidepressant Treatment on Neurocognitive Functions, Redox and Inflammatory Parameters in the Context of COVID-19.Journal of clinical medicine · 2023Article
- Potential Role of Glutathione Antioxidant Pathways in the Pathophysiology and Adjunct Treatment of Psychiatric Disorders.Clinics and practice · 2023Review
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depressive disorder (MDD) is a common mental disorder associated with a significant negative impact on quality of life, morbidity/mortality, and cognitive function. Individuals who suffer with MDD display lower serum/plasmatic total antioxidant potentials and reduced brain GSH levels. Also, F2-isoprostanes circulatory levels are increased in MDD subjects and are correlated with the severity of depressive symptoms. Urinary excretion of 8-OHdG seems to be higher in patients with MDD compared to healthy controls. Despite the fact that antidepressant drugs have been used for more than 50 years, their mechanism of action is still not fully understood. This paper examines preclinical (in vitro and animal model) and clinical literature on oxidative/antioxidant effects associated with antidepressant agents and discusses their potential antioxidant-related effects in the treatment of MDD. Substantial data support that MDD seems to be accompanied by elevated levels of oxidative stress and that antidepressant treatments may reduce oxidative stress. These studies suggest that augmentation of antioxidant defences may be one of the mechanisms underlying the neuroprotective effects of antidepressants in the treatment of MDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.